Dr.tejaswi yellapu, T21519
This is a retrospective interventional case series from 2013 to 2018 in which 4 patients were included having U/L Choroidal Osteoma complicated with CNVM. 2 of the cases were one eyed. All were treated with intravitreal bevacizumab 1.25 mg in 0.05ml. OCT and BCVA were accessed on every follow-up.
4 eyes were treated with intra-vitreal bevacizumab with a mean of 4.75 injections. 1 of 4 cases were stable with no evidence of recurrence, with a 3 doses of injection. Two case showed recurrence after 2 and 6 months which required a repeat injections. Other case showed recurrence after 15 months requiring 3 serial doses of intravitreal injections, stable on follow up.Improvement of VA in snellens chart is seen in 2 cases by 2 to 3 lines and other 2 cases no improvement. Improvement of CRT in OCT is seen in all 4 cases with resolution of sub-retinal fluid.
Intra-vitreal bevacizumab has role in CNVM secondary to choroidal osteoma in reducing CNVM and improving vision.
Leave a Comment